tbuckley/cabot-search huggingface dataset:
Medicine Mobilizes for War Against Mental Illness
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SULFAGUANIDINE TOXICITY
Authors: Seymour L. Cole
Journal: JAMA (1942)

Owing to its efficacy against the bacteria of the intestinal tract and its slow rate of absorption into the blood stream, sulfaguanidine is becoming increasingly widely used as a chemotherapeutic agent for intestinal diseases. The occurrence of severe reactions to sulfaguanidine therapy, however, apparently has not been recorded up to this time. Although Turell and Leifer<sup>1</sup>have reported a dermatitis appearing during the administration of sulfaguanidine, in their case this may have been due in part to the sulfanilamide, sulfathiazole or sulfapyridine, all of which had been given previously. Ringelman<sup>2</sup>has reported an eruption associated with sulfaguanidine therapy alone. Marshall and his associates<sup>3</sup>observed no toxic effects in a series of 25 children who were given therapeutic doses of sulfaguanidine and only mild reactions in 3 of 25 adults who received the drug. These were in the form of drug fever, unilateral conjunctivitis and a "possible mild
Genetic Differentiation of Hypothalamus Parentally Biased Transcripts in Populations of the House Mouse Implicate the Prader–Willi Syndrome Imprinted Region as a Possible Source of Behavioral Divergence: Table 1.
Authors: Anna Lorenc, Miriam Linnenbrink, Inka Montero, Markus B. Schilhabel, Diethard Tautz
Journal: Molecular Biology and Evolution (2015)
PARIS
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
US Medical School Finances
Authors: H. Paul Jolly
Journal: JAMA (1983)

The 23rd annual review of medical school finances, prepared by the Division of Operational Studies of the Association of American Medical Colleges (AAMC), is intended to reflect, through financial analysis of revenues and expenditures, the secular trends in medical education in the United States. Some sense of the growth in the enterprise during the 23-year interval from 1958-1959 to 1981-1982 may be gleaned from an examination of a few of its dimensions shown in Table 1. The number of schools has increased, candidates for both professional and academic doctorates have more than doubled, and the population of postdoctoral students has mushroomed. Full-time faculty has more than quintupled during this period. Expenditures for virtually all of the education, research, and service programs have expanded ten- to 20-fold or more. All in all, the epoch covered by this time series has been one of extraordinary growth. <h3>Background—Data Sources and Characteristics</h3> All data,
A Course of Lectures on Urine, Urinary Deposits, and Calculi
Authors: L. Beale
Journal: BMJ (1860)

THE U IFEnRous TunEs.Casts of the Renal Tubes are seldom found unmixed with other deposits.Frequently they are aceompanied with much epithelium, and in many cases blood-globules are present in considerable number.Occasionally, however, we meet with a
On the Therapeutical Action of Digitalis
Authors: E. Mackey
Journal: BMJ (1868)

<b>Rationale:</b> Idiopathic interstitial pneumonias are characterized by variable degrees of lung inflammation and fibrosis, and the mechanisms leading to these responses remain unclear. Protease activated receptor (PAR)-2, a G-protein-coupled receptor has been recognized as a key molecule in inflammation and fibrosis. In a previous study, we found that activation of PAR-2 induces transforming growth factor (TGF)-β expression and epithelial-to-mesenchymal transition (EMT) associated with lung fibrosis in vitro. We hypothesized PAR-2 inhibiting peptide (IP) might reduce bleomycin (BLM)-induced lung injury and fibrosis in vivo. <b>Methods:</b> C57BL/6 mice were used in all experiments. BLM was administered by intratracheal injection under anesthesia. PAR-2 IP was intranasally instilled half an hour before BLM injection and once daily until the end of the experiment. Blood sampling and bronchoalveolar lavage (BAL) were performed 7, 14 and 21 days after BLM instillation. The lungs were excised and the samples were used for histological analysis, RT-PCR and ELISA. <b>Results:</b> PAR-2 IP reduced BLM-induced lymphocytes in BAL fluid (BALF). Lung fibrosis was reduced in PAR-2 IP-treated BLM mice. PAR-2 IP downregulated the expression of monocyte chemotactic protein (MCP)-1 and TGF-β, and inhibited profibrotic responses, as seen by reduced collagen induction by BLM. Immunohistochemistry showed PAR-2 IP reduced BLM-induced EMT. Induction of high-mobility group box (HMGB)-1 by BLM which may mediate EMT was reduced by PAR-2 IP treatment. <b>Conclusion:</b> PAR-2 inhibition reduces BLM-induced lung inflammation and fibrosis, suggesting that PAR-2 might play a pivotal role in BLM-induced lung injury. The results could lead to new therapeutic strategies for lung fibrosis.
Coronary Restenosis.
Authors: S. D Rosen
Journal: Cardiovascular Research (1994)

Coronary Restenosis. Get access Stuart D Rosen Stuart D Rosen London, UK Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 28, Issue 2, February 1994, Page 288, https://doi.org/10.1093/cvr/28.2.288 Published: 01 February 1994
Deaths
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A 1969 Head Start medical program: implications for change, Rochester, NY
Authors: R. A. Hoekelman
Journal: JAMA (1972)

The health goals of Project Head Start were not accomplished in the Rochester, NY, 1969 Summer Head Start Medical Program. There are few available data to indicate whether these goals are being reached elsewhere. These failures and failures in reaching educational and social goals led to elimination of the Summer Head Start program in Rochester and to expansion of the year-round program. Health goals of Head Start programs and the methods of reaching them need alteration to increase prospects for success. The elimination of routine periodic physical examinations and the utilization of professional nurses as health care coordinators for children and their families is proposed as a means to conserve scarce medical manpower and to provide a mechanism for improved health care within Head Start programs and elsewhere.
Continuing Education Courses for Physicians
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Faith-Cure in the Courts.
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the Food and Drug Administration
Authors: Stuart L. Nightingale
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction
Authors: J. C. N.
Journal: American Journal of Psychiatry (1989)

The names listed below were inadvertently omitted from the Editor's "New Year's Greetings" (January 1989 issue, pp. 2-7), which is partially reprinted here: New Year's Greetings "If men could learn from history," remarked Samuel Taylor Coleridge, "what lessons it might teach us! But passion and party blind our eyes, and the light which experience gives is a lantern on the stern, which shines only on the waves behind us!" True enough, but in his moment of transient cynicism Coleridge overlooks the pleasures of reflective reminiscence—a pleasure in which the Editor annually indulges as the year comes to an end and another volume of the Journal is completed. Shuddering momentarily at the recollection of the myriads of manuscripts that have crossed his desk in seemingly endless procession, he soon remembers the hundreds of colleagues who, in selfless anonymity, have helped him in their capacity as reviewers; and his spirits rise in the realization that the time has at last come to express his deep gratitude for their invaluable contributions to their profession and their Journal during the period from November 1, 1987, to October 31, 1988. Robert L. Arnstein, M.D. Frederick K. Goodwin, M.D. Paul N. Graffagnino, M.D. Daniel R. Hanson, Ph.D., M.D. Leston L. Havens, M.D. Michael Irwin, M.D. Michael Jellinek, M.D. Jonathan E. Kolb, M.D. Bennett L. Leventhal, M.D. Allan F. Mirsky, Ph.D. Arthur J. Prange, M.D. Eric M. Reiman, M.D. Maj-Britt Rosenbaum, M.D. Roslyn Seligman, M.D. Monica N. Starkman, M.D. Peter E. Stokes, M.D. Fridolin Sulser, M.D. Ilza Veith, Ph.D., M.D. Andrew S. Watson, M.D.
Book Review Diseases of the Nose, Throat and Ear . By William Lincoln Ballenger, M.D., F.A.C.S., Late Professor of Otology, Rhinology and Laryngology, College of Medicine, University of Illinois, Chicago, Illinois. Revised by Howard Charles Ballenger, M.D., F.A.C.S., Associate of the Otho S. A. Sprague Memorial Institute Laboratory of the Children's Memorial Hospital, Chicago; Attending Otolaryngologist to the Evanston Hospital, Evanston, Illinois. 1100 pages of text. Publishers: Lea &amp; …
Journal: New England Journal of Medicine (1930)
Ker's Manual of Fevers.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Labyrinthine Giddiness
Authors: A. J. Wright
Journal: BMJ (1938)

ME]BARITSALdischarge for three months following a miscarriage.On examination the uterus was fotund to be soft and uLniformly enlarged to one and a half inches below the umbilicus.No foetal parts were felt per vaginam.The breasts were active, and the diagnosis of a normal pregnancy was made and she was discharged.Two months later she returned, having had a " flooding" ten' days previously, when she passed clots and some "white tufts."At this time the uterus was not palpable per abdomen, but was found to be enlarged per vaginam (two to three months).The breasts were still active.A positive Aschheim-Zondek reaction was obtained.As the discharge continued over a period of three weeks it was decided to perform a curettage.The curettings, however, showed only blood clot and fragments of normal-looking endometrium.There were no chorionic villi or other products of conception, and no evidence of hydatidiform mole or chorionic epi- thelioma.All these observations have been confirmed by subsequent examination of the cLurettings.Three weeks later the Aschheim-Zondek test was negative.Quite recently, eleven months after the curettage, this patient returned to hospital with a large mass in the uteruis which had extended into the vagina.Clinically the mass was diagnosed as a chorionic epithelioma, and a positive Aschheim-Zondek reaction was obtained.She was treated with radium, and a week later the test was repeated and was found to be still strongly positive.She died a day after the last test, and at the post-mortem examination a large mass of growth was found in the uterus and vagina, with metastatic nodules in the lungs.Microscopically the tumour was a typical chorionic epithelioma.The case is included in this series because of the interesting sequence of events.It is obvious that in the beginning a normal pregnancy was present; hence the positive reaction.The pregnancy terminated in an abortion, which explains the curettage findings and the negative test.Some residual chorionic tissue must have been present, since a chorionic epithelioma later developed, but at that stage it was not sufficient to give a positive Aschheim-Zondek reaction. SummaryThe results of Aschheim-Zondek tests on urines from patients with diseases of the secondary sex organs show that, with one possible exception, lesions of the breast and prostate are not associated with any increase in prolan A excretion in the urine.Among additional cases examined the positive results obtained with chorionic epi- thelioma, teratoma testis (two cases), and an uinsuspected case of pregnancy confirm previouis findings in these con- ditions, and the negative results in cases of ovarian cyst, uterine fibroids, and pituitary eosinophil adenoma are in keeping with the majority of previous observations.I should like to record my thanks to Dr.
Impact of skeletal complications on total medical care costs in lung cancer patients with bone metastases
Authors: T. E. Delea, J. M. McKiernan, M. Liss, J. S. Edelsberg, J. Brandman, J. C. Sung, M. K. Raut, G. Oster
Journal: Journal of Clinical Oncology (2004)

6064 Background: Lung cancer patients with bone metastases often experience skeletal-related events (SREs) including pathological fracture, spinal cord compression, hypercalcemia, or pain requiring surgery, radiotherapy, or opioid analgesics . Previous studies have estimated the costs of SREs by tallying costs for services specifically attributable to these events. This approach may underestimate costs if SREs have effects on other services. Methods: We used a large US health insurance claims database (7/94 - 6/02) to quantify impact of SREs on total medical care costs in patients with bone metastases of lung cancer. Subjects included in this analysis had ≥2 encounters with a diagnosis of primary lung cancer and ≥2 encounters with a diagnosis of metastases to bone. Expected total medical care costs were compared for propensity-matched samples of patients with SREs versus patients without SREs. SREs were identified based on the occurrence on or after the date of first diagnosis of bone metastases, of (1) ≥1 encounter with a diagnosis of pathological fracture, spinal cord compression, or hypercalcemia, or (2) ≥1 bone surgery or radiotherapy procedure, or (3) initiation of opioid analgesic therapy. Results: We identified 534 lung cancer patients with bone metastases, including 295 (55%) with ≥1 SRE. After matching, there were 162 patients each in the SRE and no-SRE groups with mean follow-up of 6.3 and 4.5 months respectively. In the SRE group, expected costs of care directly attributable to SREs were $9,494 per patient. Expected total medical-care costs were $28,223 greater in SRE versus no-SRE patients ($59,926 vs $31,704 in the no-SRE group). Conclusions: The costs of SREs in patients with lung cancer and bone metastases are substantial and potentially greater than previously estimated. Treatments which prevent SREs, such as the intravenous bisphosphonate zoledronic acid, may reduce these costs. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Pharmaceuticals Corp. Novartis Pharmaceutical Corp. Novartis Aventis Oncology Aventis Oncology
Criteria in the choice of a computer system. I. The computer in theory
Authors: S. Raymond
Journal: JAMA (1974)

THIS article reviews current laboratory computer systems from one user's viewpoint, and suggests a new criterion for evaluating them. The personal opinions expressed here are based on six years of intensive experience in designing and implementing a computer system for our laboratory; they derive whatever interest they possess from these facts: (1) our system has been operating successfully for the past four years, (2) it has won complete acceptance among the professional staff it serves, (3) it saves our hospital considerably more in actual dollars than it costs, and (4) it is ready for use in other hospitals. It will be seen that these opinions do not agree with important, commonly held opinions about computer systems, their design, their objectives, and especially the way computer technology is now applied. Computer systems, in my opinion, exist to facilitate the care of the patient, rather than to exhibit the technical accomplishments of